Amphastar Pharmaceuticals, Inc.
AMPH· Nasdaq
AMPHAmphastar Pharmaceuticals, Inc.
Filed Mar 15, 2021 · 10-K · 74 days after period end · 0001297184-21-000008
derived · Computed from the longer spans the company filed.
| Metric | Q4 2020dderived from reported figures | Q4 2019 | Q4 2018 | Q4 2017 |
|---|---|---|---|---|
| Revenue | $95.92M | $83.38M | $89.69M | $60.40M |
| Net Income | -$6.27M | -$1.03M | $1.87M | $1.47M |
| EPS Diluted | — | -$0.02 | $0.04 | $0.02 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Amphastar Pharmaceuticals, Inc. · CIK 1297184 · Engraved from SEC EDGAR
ended Dec 31, 2020 · filed Mar 15, 2021 · 74 d after period end
